Analysts See $-0.01 EPS for ProMIS Neurosciences Inc. (PMN)

March 14, 2018 - By Clifton Ray

 Analysts See $ 0.01 EPS for ProMIS Neurosciences Inc. (PMN)

Analysts expect ProMIS Neurosciences Inc. (TSE:PMN) to report $-0.01 EPS on March, 21.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, ProMIS Neurosciences Inc.’s analysts see 0.00 % EPS growth. The stock decreased 3.30% or $0.02 during the last trading session, reaching $0.44. About 112,900 shares traded. ProMIS Neurosciences Inc. (TSE:PMN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company has market cap of $96.83 million. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. It currently has negative earnings. The firm applies its thermodynamic, computational discovery platform?ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.

More notable recent ProMIS Neurosciences Inc. (TSE:PMN) news were published by: which released: “ProMIS Neurosciences Inc.” on October 18, 2016, also with their article: “ProMIS Neurosciences Announces Trading on OTCQB Venture Market” published on December 04, 2017, published: “ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows …” on January 23, 2018. More interesting news about ProMIS Neurosciences Inc. (TSE:PMN) were released by: and their article: “ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results” published on March 14, 2018 as well as‘s news article titled: “ProMIS Neurosciences Announces Gross Proceeds of $1484498 Related to the …” with publication date: March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.